NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma
NCT01311687: Phase 3 - Efficacy & Safety of Pomalidomide & Low dose dex Vs High-Dose Dex - NIMBUS
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib